BTIG Reiterates Buy Rating on Glaukos Corporation
BTIG reaffirms its buy rating on Glaukos with a $162 price target.
Key Points
- BTIG reiterated its buy rating on Glaukos Corporation with a $162 price target on June 10, 2026.
- Shares of Glaukos (NYSE: GKOS) are trading around $124.22 with a market cap of about $7.45 billion.
- Insiders recently bought shares, and analysts like Citigroup also maintain a buy rating with a $162 target.
BTIG has reiterated its buy rating on Glaukos Corporation (NYSE: GKOS), setting a price target of $162. This reaffirmation came on June 10, 2026, as Glaukos shares traded at approximately $124.22.
Glaukos Corporation Stock Snapshot
Shares of Glaukos are trading near $124.22, with a market cap of about $7.45 billion. The company has a forward P/E ratio of 285.8 and a beta of 0.815, indicating modest volatility compared to the market. Over the past year, the stock has ranged between $73.16 and $148.11, with moving averages of $124.86 for 50 days and $107.13 for 200 days. The company maintains a strong liquidity position with a current ratio of 5.43 and a quick ratio of 4.43, alongside a debt-to-equity ratio of 15.78.
Recent Earnings
In its recent earnings, Glaukos reported revenue of $551.3 million, reflecting a growth of 41.2%. However, the company is not currently profitable, with a net margin of -34.3% and a return on equity of -26.4%. The next earnings release is scheduled for April 29, 2026.
Insider Buying and Selling at Glaukos Corporation
On May 28, 2026, several insiders, including Marc Stapley, Denice Torres, Leana Wen, Mark Foley, and Aimee Weisner, purchased shares of Glaukos. Each insider acquired between 1,878 and 2,987 shares, although the transaction values were not specified.
Analysts Set New Price Targets
On June 11, 2026, Citigroup maintained its buy rating on Glaukos with a price target of $162. BTIG also reiterated its buy rating with the same target on June 10, 2026. The consensus among analysts is a strong buy, with an average target price of $156.33 based on 12 analyst opinions.
About Glaukos Corporation
Glaukos Corporation, based in Aliso Viejo, California, is a healthcare company specializing in ophthalmic pharmaceuticals and medical technologies. It develops treatments for glaucoma, corneal disorders, and retinal diseases. Its products include micro-bypass stents like iStent and iStent inject W, as well as the iDose TR for intraocular pressure reduction. Glaukos also offers the iLink device for keratoconus treatment and is working on the ILution platform for eye disorders.
Bottom Line
BTIG's reiteration of a buy rating signals continued confidence in Glaukos Corporation's potential. Investors often track these ratings to gauge sentiment, although it's important to remember that these are based on past data and may not reflect current conditions. Glaukos remains a key player in ophthalmic medical technology, with strong analyst support and insider buying activity.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.